Anti-glutamatergic effect of riluzole: comparison with valproic acid.
Neuroscience
; 147(1): 136-45, 2007 Jun 15.
Article
en En
| MEDLINE
| ID: mdl-17507170
Riluzole, an anti-amyotrophic lateral sclerosis drug, known to decrease presynaptic glutamate release, is viewed as a candidate supplementary medication for epilepsy. In the present study, we compared the effects of riluzole and valproate (VPA) in the pilocarpine-induced limbic seizure model and in the gamma-hydroxybutyrate lactone (GBL)-induced absence seizure model. We applied immunohistochemical study for vesicular transporter 1 (VGLUT1) and extracellular recording in the rat dentate gyrus of both pilocarpine- and GBL-induced seizure models to measure effects of riluzole and VPA. Both VPA and riluzole treatments reduced VGLUT1 immunoreactivity. Riluzole treatment completely inhibited pre-ictal spikes and spike-wave discharges in the pilocarpine- and GBL-induced epilepsy models, whereas VPA partially inhibited these phenomena. In both seizure models, the anti-epileptic effects of VPA and riluzole are basically related to anti-glutamatergic (reducing field excitatory postsynaptic potential slope and excitability ratio), not GABAergic (paired-pulse inhibition) effect. Riluzole was more effective at reducing seizure activity in both epilepsy models than VPA. These results suggest that riluzole is a potential antiepileptic drug with activity against limbic seizure and absence seizure.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Convulsiones
/
Estado Epiléptico
/
Ácido Valproico
/
Riluzol
/
Proteína 1 de Transporte Vesicular de Glutamato
/
Anticonvulsivantes
Límite:
Animals
Idioma:
En
Revista:
Neuroscience
Año:
2007
Tipo del documento:
Article
País de afiliación:
Corea del Sur
Pais de publicación:
Estados Unidos